Program
HDG1901
A development code.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 20 open or running | phase 3since Dec 10, 2024 | Sep 24, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2024First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06634927 · 68 enrolled · China
- Dec 10, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06739044 · 494 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06739044Diabetes Mellitus, Type 2 · China | 3 | Completed | Oct 11, 2024 | 494 |
| NCT06634927Diabetes Mellitus, Type 2 · China | 1 | Completed | Nov 14, 2024 | 68 |
How it is read
Names in the registry
- “HDG1901”, 2 entries
Codes read as this program: HDG1901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.